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Introduction 
 Most of countries around the globe are facing the 
challenges of growing healthcare demand with limited 
available resources 
 Era of 'the best care that medicine can provide’ is slowly 
being replaced by a new slogan, 'the best care we can 
afford' (Wettermark et. al. 2009) 
 In middle and lower income countries, expenditure on 
pharmaceuticals ranges from 20 to 60% of total spending 
on health (Godman et al. 2010) 
 Pressures to control pharmaceutical expenditure have led 
to increased prescribing and dispensing of low cost 
generic drugs (Araszkiewicz et al. 2008) 
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Leading Causes For Increase In Healthcare Costs 
 
  
• Ageing population 
•  Increase in incidence of diseases 
•  Health technologies advancement 
• Administrative cost 
 
Need cost-effective approaches to ensure 
better use of limited health care dollars 
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• In the USA, the FDA, which is responsible for registering and marketing 
authorization, defines generic medicine as ‘a medicine that is identical, or 
bioequivalent, to a brand name medicine in dosage form, safety, strength, 
route of administration, quality, performance characteristics, and intended 
use’ 
• The EMA defines generic medicines as “a medicinal product which has the 
same qualitative and quantitative composition in active substances and the 
same pharmaceutical form as the reference medicinal product, and whose 
bio-equivalence with the reference medicinal product has been 
demonstrated by appropriate bio-availability studies”* 
 
* Definition adopted by the Malaysian NPRA 
 
                 
Definition of ‘Generic Medicine’ 
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The Importance of Generic Pharmaceuticals 
•  Medicines - use of sub standard and counterfeits 
•  Medicines - inappropriate and ineffective use 
•  Medicines - underuse of generics 
•  Health care products & services - overuse 
•  Health workers - inappropriate or costly staff mix 
•  Health care services - inappropriate hospital                   
      admission and length of stay                
•  Health care services - inappropriate hospital size 
•  Health care services - medical errors and  
      suboptimal quality of care 
•  Health system leakages - waste, corruption & fraud 
•  Health interventions- inefficient mix/inappropriate    
      strategies 
 
The World Health Report (2010) identified the following 
ten leading cause for health systems inefficiency: 
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The Importance of Generic Pharmaceuticals 
o Lower prices 
o Competition and innovation 
o Access to essential medicines. 
o Supply continuity. 
o Economic development and employment 
o Savings for national healthcare systems 
Ref:  Brems et al, Journal of Generic Medicines, 2011 
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Ref: IMS Health Dec 2016 
 
Utilization of Generic Medicines 
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Ref: Hogerzeil, H. V., Liberman, 
J., Wirtz, V. J., Kishore, S. P., 
Selvaraj, S., Kiddell-Monroe, R., 
... & Lancet NCD Action Group. 
(2013).. The Lancet, 
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Ref: Dylst,P et al. Appl Health Econ Health Policy. 2013 Jul 12.  
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Each European country has different approach in 
improving generic medicine utilization.  
 
Examples of ongoing initiatives to increase the 
prescribing of generic products broken down by the 4Es 
which includes: 
Education 
Engineering 
Economics 
Enforcement 
 
 
Ref: Godman et al. Generics and Biosimilars Initiative, 2010 
Initiatives to Reduce Prescription Cost: The European  
Experience 
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Opportunities for  Generic Use 
Product 
Trade name 
Generic name Company 
Sales figures for 
2002 
Sales figures for 
2003 
Sales figures for 
2004 
Sales figures 
for 2006 Patent 
Expiry 
Patent 
Extension 
(US$ billion) (US$ billion) (US$ billion) (US$ billion) 
Company IMS Company IMS Company IMS 
Company 
Projection 
Lipitor® Atorvastatin Pfizer 7.9 8.6 9.23 10.3 10.86 12 8.32 30/05/06 24/09/09 
Zocor® Simvastatin Merck 5.6 6.2 5.01 6.1 5.2 5.9 3.06 24/04/01 23/12/05 
Celebrex® Celecoxib Pfizer 3 NA 1.9 2.5 3.3 NA 1.61 30/11/13 
Fosamax® Alendronate Merck 2.2 NA 2.5 NA 3.1 NA 1.89 4/11/2003 6/8/2007 
Zoloft® Sertraline Pfizer 2.74 NA 3.1 3.4 3.36 NA 2.04 20/08/02 30/12/05 
Zyprexa® Olanzapine Eli-Lilly 3.6 4 4.27 4.8 4.42 4.8 2.32 23/04/11 
Risperdal® Risperidone 
Johnson & 
Johnson 
2.1 NA 2.5 NA 3 NA 2.44 14/02/06 29/12/07 
Effexor® Venlafaxine Wyeth 2 NA 2.7 NA 3.3 3.7 2.54 13/12/02 13/12/07 
Norvasc® Amlodipine Pfizer 3.8 4 4.33 4.5 4.46 4.8 2.59 25/02/03 31/07/06 
Plavix® Clopidrogrel Sanofi-Aventis 3.1 NA 4.2 3.7 5.2 5 2.83 12/2/2008 17/11/11 
Prevacid® Lansoprazole Takeda 3.7 3.6 3.3 4 3.1 3.8 3.45 29/07/05 10/5/2009 
Advair® 
Fluticasone; 
Salmetrol 
GSK 2 NA 3.6 NA 4.5 4.7 3.8 12/2/2008 
Nexium® Esomeprazole AstraZeneca 1.97 NA 3.3 3.8 3.88 4.8 4.94 1/9/2007 1/9/2007 
Ref : Journal of Generic Medicines 2008; 5(3): 201-208.  
Ref: Drug Discovery Today 2005; 10(1): 739-742. 
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Savings Via Generics Use: Malaysian Local Data 
In Malaysia, generic medicines are much less expensive than innovator brands and 
generally costing between 30 to 90 per cent less 
Ref: Ping, Bahari & Hassali ,2008 Ref:  Shafie &  Hassali, 2008. 
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o Subjected to similar regulatory control 
o Much cheaper 
– Clopidogrel  75mg  RM 6.80  (USD 1.80) vs  RM 2.10 (USD 0.60) per tablet 
– Atorvastatin 20mg  RM 4.00 (USD 1.05) vs  RM 1.20 (USD 0.32) per tablet 
– Simvastatin 20mg  RM 2.10 (USD 0.60) vs  RM 0.60 (USD 0.15) per tablet 
 ~ RM 6.80 per tablet ~ RM 2.10 per tablet 
Generic Pricing: Experience From Malaysia 
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        Generic Medicines Policy in Malaysia 
• Prescribing in generic International Non-proprietary 
Name (INN) shall be practised at all channels 
• Procurement of all medicines by generic INN shall be 
promoted 
• In selection for procurement, priority shall be given 
to domestically manufactured medicines 
• All dispensed medicines shall be labelled 
prominently with the generic INN of the medicine 
with or without the brand name 
• A list of interchangeable and non-interchangeable 
medicines shall be available 
• Generic substitution shall be permitted and 
legislated for all interchangeable medicines 
• Appropriate incentives to promote the use of 
generic medicines and their production 
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              Generic Medicines Policy in Malaysia 
1. Procurement of multi-source products by generic 
names shall be promoted to foster healthy 
competition in drug pricing. 
 
2. Appropriate incentives to promote the use of 
generic drugs and their production in the country 
shall be introduced. 
 
3. A formulary of interchangeable generic drugs and 
the list of products that cannot be substituted shall 
be made available. 
 
4. All dispensed drugs shall be labelled with the generic 
(INN) name of the medicine with or without the 
brand name. 
 
5. Generic prescribing and labelling should be 
encouraged, and generic substitution permitted and 
eventually legislated, in order to improve 
affordability of medicines. 
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Malaysian Economic Transformation Program (ETP) 
• Launched on 25 September, 2010, the ETP was formulated as part 
of Malaysia's National Transformation Programme. 
• Aim: to elevate the country to developed-nation status by 2020, 
targeting GNI per capita of US$15,000.  
• The ETP's targets for 2020 will be achieved through the 
implementation of 12 National Key Economic Areas (NKEA). 
• These areas representing economic sectors which account for 
significant contributions to GNI.  
• The ETP represents the catalyst for economic growth and 
investments needed for Malaysia to achieve high-income status by 
2020.  
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National Key Economic Areas (NKEA) 
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ETP Official Website 
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List of Entry Point Projects (EPP) 
EPP 1: Mandating Private Insurance for Foreign Workers  
EPP 2: Creating Supportive Ecosystem to Grow Clinical Research 
EPP 3: Malaysian Pharmaceuticals – Increasing Local Generic  Manufacturing for Exports  
EPP 4: Reinvigorating Healthcare Travel 
EPP 5: Creating a Diagnostic Services Nexus  
EPP 6: Developing a Health Metropolis: A World-Class Campus for  Healthcare and Bioscience 
EPP 7: Upscale Malaysia’s In-Vitro Diagnostic (IVD) Industry  
EPP 8: Build Malaysian Showcase on Next Generation of Core Single Use Device (SUD)  
Products  
EPP 9: Become the Hub for High-Value Medical Devices Contract Manufacturing 
EPP 10: Malaysian Clinical Device Champions  
EPP 11: Medical Equipment Supply Chain Orchestration  
EPP 12: Medical Refurbishment Hub  
EPP 13: Build Medical Hardware and Furniture Cluster  
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ETP: Health Care EPP3 
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EPP 3: Malaysian Pharmaceuticals – Increasing Local 
Generic Manufacturing for Exports  
A few of the strategies under EPP were to: 
a) Promote Malaysia as a member in the Organisation of the 
Islamic Cooperation and the Pharmaceutical Inspection 
Convention and Pharmaceutical Inspection Cooperation 
Scheme (PIC/S) to widen the export opportunities 
b) Upgrade the domestic manufacturing plants 
c) Have good relationships between multinational corporations and domestic 
manufacturers 
d) Ministry of Health (MOH) off-take procurement agreement with new local 
manufactured pharmaceuticals. 
e) Develop comprehensive national pharmaceutical data 
 
 
 
 
MOH Off-take Agreement (3+2) 
The MOH: main buyer of the manufacturer’s future production for 3 years with the 
condition that the product must be manufactured in Malaysia. The agreement could be 
extended for another 2 years if the manufacturer demonstrates that the product can be 
registered and marketed in other countries 
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Pharmaceutical Inspections Cooperation Scheme 
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Pharmaceutical Inspections Cooperation Scheme 
• Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-
operation Scheme (jointly referred to as PIC/S) are two international instruments 
between countries and pharmaceutical inspection authorities, which provide 
together an active and constructive co-operation in the field of GMP.  
• Malaysia’s participation as a member of the Pharmaceutical Inspection 
Cooperation Scheme (PIC/S) since 2002. 
• PIC/S is an international instrument between countries and pharmaceutical 
inspection authorities, which together provide  an active and constructive 
cooperation in the field of GMP. 
• Pharmaceutical products from members of PIC/S are of high quality because 
PIC/S ensures that all members comply with PIC/S standards at all times (i.e. 
assessment of new applicants and reassessment of existing member 
inspectorates). 
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37 Slovenia Agency for Medicinal Products and Medical Devices 
38 South Africa Medicines Control Council 
39 Spain 
Agencia Española del Medicamento y Productos Sanitarios (Spanish Agency of Drugs and 
Health Products) 
40 Sweden   Medical Products Agency 
41   Switzerland   Swiss Agency for Therapeutic Products 
42 Ukraine   State Administration of Ukraine on Medicinal Products 
43 United Kingdom   Medicines and Healthcare Products Regulatory Agency 
44 
United States of 
America 
United States Food and Drug Administration 
26 
Ref: Pharmaceutical Inspection Co-operation Scheme (PIC/S). Members and partners. 2013 [updated 2013 December 12; cited 2013 December 20]; 
Available from: http://www.picscheme.org/members.php. 
 
 
 
Members of PIC/S 
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24 Latvia 
Zāļu Valsts Aģentūra (State Agency of Medicines) 
 
25   Liechtenstein Amt für Gesundheit (Office of Healthcare) 
26   Lithuania State Medicines Control Agency 
27   Malaysia  National Pharmaceutical Control Bureau 
28 Malta Medicines Authority Malta 
29   Netherlands Inspectie voor de Gezondheidszorg (Inspectorate of Health Care) 
30 New Zealand Medicines and Medical Devices Safety Authority 
31 Norway   Norwegian Medicines Agency 
32 Poland   Main Pharmaceutical Inspectorate 
33 Portugal 
Autoridade Nacional do Medicamento e Produtos de Saúde IP (National Authority of 
Medicines and Health Products IP) 
34 Romania National Agency for Medicines and Medical Devices 
35 Singapore Health Sciences Authority 
36 Slovak Republic State Institute for Drug Control 
27 
 
Members of PIC/S 
• Malaysia become member of PIC/S at 1st January 
2002. 
 
• Malaysia is the s c  country Asian country to gain 
accession after Singapore. 
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Current Situation in Malaysia 
 
• Despite the availability of some pro-generic policies, there is a lack of implementation 
and enforcement through legislations 
• In comparison with developed countries (e.g. USA, Australia) where pro-generic 
medicine policies and initiatives are in place including: 
– generic substitution policy 
– interchangeable medicines formulary 
– differential copayment system that encourage patients to accept generic medicines 
– incentives/profit margin to encourage pharmacists to recommend generic 
medicines 
– extensive educational campaigns targeting both healthcare professionals and 
patients 
• However, the situation in Malaysia is relatively comparable with south-east Asian 
countries such as Thailand. 
• Moreover, the situation in Malaysia is relatively comparable with Japan in terms of the 
challenges related to negative perceptions and misconceptions about safety, quality and 
efficacy of generic medicines among healthcare professionals and medicine consumers. 
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Consumers: Major barriers to acceptance 
includes: 
• Preference for GP’s prescribed brand of 
medicine, 
• Concern over safety and efficacy of generic 
medicines, 
• Concern about adverse effects from generic 
brands, and confusion that may arise from 
using different brands of the same medicine. 
 
 
Issues Related To Generic Medicine Use 
Ref: Hassali MA et al. Int J Pharm Pract. 2009 Apr;17(2):79-88 
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• A  study published in JAMA March 2008 evaluated the influence of 
drug price on the efficacy of medical therapies.  
• A total of 82 healthy paid volunteers were recruited into an 
established pain study (using electrical shocks administered to the 
wrist area).  
• Subjects were told that they would receive an FDA-approved opioid 
preparation, although in reality they were given a placebo.  
• Subjects were randomized into 2 groups: those that were told the 
drug was a standard price and those that were told the drug had 
been discounted (no reason given for the discount).  
 
People Assume Expensive Drugs Work Better!!! 
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Results showed a significantly greater reduction in pain (85%) in the standard price 
group compared with the discount price group (61%). Similar results were noted when 
evaluating results from the most painful shocks for each participant (80% vs. 56% 
reduction).  
 
The difference in placebo response to commercial features may explain why high-cost 
medical therapies such as COX-2 inhibitors were more popular with the general public 
compared with alternative NSAIDs.  
 
Clinicians should be aware of this potential problem and de-emphasise potentially 
deleterious commercial factors such as the lower cost of generic substitution when 
prescribing for their patients.  
       People Assume Expensive Drugs Work Better!!! 
Ref:  Waber, R. L., Shiv, B., Carmon, Z., & Ariely, D. (2008). Jama, 299(9), 1016-7. 
Kami Memimpin  We Lead 
Issues Related To Generic Medicine Use 
Prescribers/Pharmacists: Major barriers to 
acceptance includes: 
• Possibility of patient confusion and a low 
level of confidence with generic medicines. 
• Loyalty to companies involved in research 
and development. 
• Lack of knowledge on issues surrounding 
bioequivalence testing for generic 
medicines. 
Ref: Hassali, M. A., Wong, Z. Y., Alrasheedy, A. A., Saleem, F., Yahaya, A. H. M., & 
Aljadhey, H. (2014).. Health policy, 117(3), 297-310. 
Ref: Chong, C. P., Hassali, M. A., Bahari, M. B., & Shafie, A. A. (2010).  Health 
Policy, 94(1), 68-75. 
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• The majority of the respondents (85 
%) claimed that they actively 
prescribed generic medicines in their 
practice. 
 
• Only 5% of the respondents correctly 
identified the Malaysia’s National 
Pharmaceutical Control Bureau’s 
bioequivalence standard for generic 
products 
 
• As many as 52% of the respondents 
thought that manufacturing standards 
for generic medicines were not as 
stringent as for branded products. 
       Prescribers Awareness On Issues Surrounding Generic 
Medicines 
Ref: Chua, G. N., Hassali, M. A., Shafie, A. A., & Awaisu, A. (2010).. Health policy, 95(2), 229-235. 
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Educational Impact among Prescribers on Generic Medicine Use 
• Education increases the doctor's 
knowledge of the biochemical standards of 
the National Pharmaceutical Control 
Bureau of Malaysia (33% vs 86.7% for 
before and after intervention). 
• It also enhances doctors' knowledge of 
safety, bioequivalence, efficacy of generic 
drugs. 
• However, education does not have a 
positive impact on the doctor's perspective 
on how to write a prescription using a 
generic drug name. 
Ref: Hassali, M. A., Wong, Z. Y., Alrasheedy, A. A., Saleem, F.,  
Mohamad Yahaya, A. H., & Aljadhey, H. (2014).. SAGE Open Medicine. 
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Educational Impact among Prescribers on Generic Medicine Use 
• Education increased the doctor's 
knowledge of the biochemical standard of 
the National Pharmaceutical Control 
Bureau of Malaysia (3.6% vs. 32.1% for pre-
and post-intervention) 
• It also increased the doctor's knowledge of 
safety, biochemistry, efficacy of generic 
drugs 
• Education has a positive impact on the 
doctor's perspective on generic drugs. 
Ref: Kumar, R., Hassali, M. A., Alrasheedy, A. A., Saleem, F., Kaur, N., & Wong, Z. Y. 
(2015. Journal of Generic Medicines, 12(1), 4-10. 
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Good References For Busy Practitioners 
Ref: McLachlan, A. J., Ramzan, I., & Milne, R. W. (2007).. Australian Prescriber, 30(2), 41-3. Ref: Birkett, D. J. (2003). Australian Prescriber, 26(4), 85-7. 
Kami Memimpin  We Lead 
Promoting Quality Prescribing 
Ref: Schiff & Galanther, JAMA 2009 
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Issues Related to Generic Medicines Use: Generic Manufacturers 
Generic Manufacturers: Major barriers to local 
production includes: 
 
 Patent clustering (i.e. acquisition of multiple  
patents surrounding the basic patents of the  
drug products) by innovator companies 
 
 Market competition from imported generics 
 
 Earlier entry of imported generic medicines into  
the Malaysia drug market was due to trade policy  
initiatives and the difficulty of local generic  
drug manufacturers in conducting bioequivalence  
(BE) studies. 
 
 BE centres are mostly university based and  
 non-profit orientated 
 
 As of 28.4.2016, there are only 5 local  
accredited BE centres. 
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Role of Universities In Establishing BE Studies Centres 
• The Working Committee for BE Studies 
which was formed in September 1999, 
comprising of representatives from 
Universiti Sains Malaysia (USM), University 
of Malaya (UM), National University of 
Malaysia (UKM), International Medical 
University (IMU), National Pharmaceutical 
Regulatory Agency (NPRA) and the 
pharmaceutical industry. The members 
were officially appointed to undertake the 
task of formulating an action plan for the 
conduct of BE studies in Malaysia through 
collaborative efforts. 
 
• Publication of the 'Malaysian Guidelines for 
the Conduct of Bioavailability and 
Bioequivalence Studies' marked the first 
outcome of this committee's objectives.  
Lab Photos : Thanks to Prof Yuen Kah Hay, PhD 
       LC-MS/MS at USM BE Lab 
HPLC with UV-Fluorescence Detection at USM BE Lab 
Plasma sample preparative room at USM BE Lab 
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Bioequivalence in Malaysia 
• The Malaysia Drug Control Authority (MDCA) at its 92nd meeting in 1999 decided 
to include BE studies requirements for the registration of generic products of 
certain categories of oral, immediate-release products to ensure 
interchangeability between innovator and generic medicines 
 
Adopted from the ‘Note for 
Guidance on the Investigation 
of Bioavailability and 
Bioequivalence , The 
European Agency for the 
Evaluation of Medicinal 
Products, ..with some 
adaptation for Malaysian  and  
ASEAN  
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Press Release 
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1 
• Agreement, cooperation and communication between pharmacists and medical 
practitioners are important for the successful substitution.  
2 
• Physicians should be able to disallow generic substitution for the cases in which 
generic substitution is not appropriate 
3 
• Patients should be given the opportunity to make an 
informed choice to consume either branded original medicines or generic 
medicines.  
4 
• Need of guide on therapeutically interchangeable drug products to help 
healthcare professionals to perform generic substitution appropriately and to 
avoid any pitfalls or errors that may arise from inappropriate generic substitution 
E.g. British National Formulary (BNF) in the United Kingdom (UK), the Schedule of Pharmaceutical Benefit 
Scheme (PBS) in Australia and the lists of interchangeable products in Finland and Sweden 
  
 
Holistic Approach for GS 
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Generics Medicine Policy in Qatar 
• The Qatari pharmaceutical market 
reached a value of Qatari Rial 1.43 
billion (US$392.6 million) in 2010.  
• Spending on medicines and 
pharmaceuticals in 2009 and 2010, as 
a percentage of total public-sector 
spending, was US$138 million (9%) 
and US$143 million (8%), respectively.  
• The retail prices of medicines remain 
among the highest in the Middle East. 
Ref: Ibrahim MI (2015), GaBI Journal 
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Generics Use in Qatar 
• Currently, there are no national generic medicine prescribing and 
dispensing policies in Qatar, and the obligation of prescribing and 
dispensing brand-name or generic products, especially in 
community practices, lies with the general practitioner and the 
pharmacist, respectively 
 
• There is no official policy on the bioequivalence of generic 
medicines, although the government is promoting their use. 
Business Monitor International (BMI) has reported that there is 
extensive use of branded medicines in Qatar’s healthcare facilities 
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Qatari Generic Drug Market Forecast 
• BMI View: Despite their relatively 
small market share, generic drug sales 
in Qatar will experience significant 
growth over the forecast period.  
• Pro-generic policies, as well as the 
effects of patent protection loss, will 
contribute to generic medicines 
market expansion.  
• The gradual development of drug 
manufacturing facilities in the country, 
albeit still insignificant, will also 
contribute to support generic 
medicines sales over the long term 
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Community Pharmacist Study On Generic Medicines in Qatar 
• 72 % of the pharmacists supported 
generic substitution for brand name 
drugs in all cases  
• Majority (93 %) agreed that pharmacists 
should be given generic substitution 
right 
• 61 % o considered lack of proven 
bioequivalence to original brands as an 
important barrier for selecting generic 
medicines  
• 55 % rated ‘‘lack of policy for directing 
the practice of generic medicine’’ as an 
important barrier  
Ref: Awaisu, A., Kheir, N., Ibrahim, M. I. M., El-Hajj, M., Hazi, H., Khudair, N., & Barazi, R. (2014). International journal of clinical pharmacy, 36(2), 394-404. 
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Qatari National Health Strategy 2011–2016 Targets 
Goal  Projects Outcomes/ 
Objectives 
 
Outputs Outputs Baseline 
and Targets to 
2016 
National health 
policy 
Healthcare 
products 
To ensure 
effective use, 
safety, and 
quality of 
healthcare 
products by 
enhancing 
healthcare 
products 
regulation 
 Education 
program for 
health 
professionals 
on 
narcotics and 
generic use 
Target: 
Establishment 
of 
national 
formulary 
(milestone) 
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Recommendations to Encourage Generics Use in Qatar: A 
  Personal View 
• Policymakers should establish a sound generic medicine policy and 
guidelines for the State of Qatar 
• There is a need to assess the knowledge, attitudes, and practices on 
generic substitution, and the need for educational interventions of 
physicians and other healthcare professionals in Qatar 
• There is a need to build consumer confidence with generics 
• There is a need to educate the final year pharmacy and medical students 
regarding generic medicines where they will be the future drug 
dispensers and prescribers 
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Current Malaysian MOH Effort in Promoting Use of Generic Medicines 
 
• Review of current policy - Master Plan of Action 
• Nationwide educational road show 
– Generic Medicines Awareness Program (GMAP) 
– Know Your Medicine Campaign 
• Development of educational booklet for 
– Healthcare Providers 
– Consumers 
• Addressing The Missing Part 
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Master Plan of Action 
• In September 2013, a workshop involving 
relevant stakeholders from the government 
agencies and private institutions was 
conducted towards preparation of Master 
Plan of Action for second term of MNMP. 
• Alongside the formation of the revised 
edition of MNMP, an appropriate and 
practical Plan of Action was developed based 
on the newly-organized components and the 
strategies outlined in the policy. 
• With the reconciliation of efforts from all the 
stakeholders, it is very much anticipated that 
the implementation of the Plan of Action will 
bring a remarkable impact to the health of 
the nation.  
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Generic Medicines Awareness Program (GMAP) 
• Nationwide road show to 
improve prescribers’ 
understanding about generic 
medicines. 
 
• Involves different stakeholders 
including NPCB, policy maker, 
generic manufacturers, doctors, 
pharmacists and etc. 
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Generic Medicines Awareness Program (GMAP) 
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The "Know Your Medicine" campaign is a project jointly organized by the 
Ministry of Health (MOH) and the Consumers Association of Malaysia 
(FOMCA). It was initiated in 2007.  
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Know Your Medicine Campaign 
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Know Your Medicine Campaign  
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Publication of Educational Booklet on Generic Medicine 
for Healthcare Professionals 
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Educational Booklet on Generic Medicine for Patients/Consumers 
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Snapshot of Educational Booklet on Generic Medicine 
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Educational Posters on Generic Medicine for Patients/Consumers 
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• Generic medicines provide the same quality, safety 
& efficacy as original branded product. 
 
 
• Allowing effective competition between generic and 
innovator medicines is crucial for lowering 
pharmaceutical cost  and  stimulating innovation.  
 
 
• Economically priced generic medicines provide a 
cost-effective means of controlling the fastest 
growing budget item in the healthcare industry: The 
pharmaceuticals! 
Take Home Messages 
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